Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen : Astellas' Biologics License Applications for Bladder Cancer Drug Candidate Accepted for Priority Review by FDA

04/19/2021 | 09:17am EDT


ę MT Newswires 2021
All news about SEAGEN INC.
07/30SEAGEN : Oppenheimer Adjusts Seagen PT to $210 From $208 Following Strong Q2 Res..
MT
07/29SEAGEN : Q2 Loss Widens Amid Higher Revenue, Reaffirms Guidance -- Stock Up 2% A..
MT
07/29SEAGEN : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
07/29SEAGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
07/29Seagen Inc. Reports Earnings Results for the Second Quarter Ended June 30, 20..
CI
07/29SEATTLE GENETICS : Q2 Earnings Snapshot
AQ
07/29SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
07/29SEAGEN : Earnings Flash (SGEN) SEAGEN Reports Q2 Revenue $388.5M, vs. Street Est..
MT
07/29SEAGEN : Reports Second Quarter 2021 Financial Results
BU
07/29Seagen Inc. Provides Earnings Guidance for 2021
CI
More news
Financials (USD)
Sales 2021 1 505 M - -
Net income 2021 -418 M - -
Net cash 2021 2 642 M - -
P/E ratio 2021 -70,9x
Yield 2021 -
Capitalization 29 694 M 29 694 M -
EV / Sales 2021 18,0x
EV / Sales 2022 12,2x
Nbr of Employees 2 092
Free-Float 99,3%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 163,21 $
Average target price 185,17 $
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-6.81%28 780
MODERNA, INC.269.97%155 195
LONZA GROUP AG26.48%59 070
IQVIA HOLDINGS INC.39.45%47 899
CELLTRION, INC.-24.93%31 463
PHARMARON BEIJING CO., LTD.88.66%25 501